Revisiting the Genomic and Transcriptomic Landscapes From Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine.

Revisiting the Genomic and Transcriptomic Landscapes From Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine.

Publication date: Nov 26, 2019

Gynaecological malignancies such as breast, ovarian and cervical cancers have become an important public health problem. Detection of molecular alterations in cancer research is fundamental since it can reveal specific pathogenic patterns and genes that could serve as markers. Our aim was to characterize common genomic and transcriptomic signatures for the three gynaecologic malignancies with the highest incidence and mortality to try to identify new molecular markers, therapeutic targets and molecular signatures.

Here we analysed a total of 723 microarray libraries corresponding to equal number of breast, ovary and cervical cancer and non-cancer patient samples. Copy number variation (CNV) was carried out using 428 libraries and transcriptomic analysis using the 295 remaining samples.

Our results showed that breast, ovary and cervical malignancies are characterized by gain of 1q chromosome. At transcriptomic level, they share 351 coding and non-coding genes, which could represent core transcriptome of gynaecological malignancies. Pathway analysis from the resulting gene lists from CNV and expression showed participation in cell cycle, metabolism, and cell adhesion molecules among others.

Chromosome 1q characterize the gynaecological malignancies, which could harbour a richness of genetic repertoire to mine for molecular markers and targets, particular gynaecologic expression profile, containing FANCI, FH and MIR155HG among others, could represent part of the transcriptomic core for diagnostic test and attractive therapeutic targets. It may not be long before every human cancer sample is profiled for a detections test to ascertain a molecular diagnosis and prognosis and to define an optimal and precise treatment strategy.

Taniguchi-Ponciano, K., , Huerta-Padilla, , Baeza-Xochihua, Ponce-Navarrete, G., Salcedo, E., Gomez-Apo, E., Chavez-Macias, L., Aviles-Duran, J., Ruiz-Sanchez, H., Valdivia, A., Peralta, R., Romero-Anduaga, H., Rosas-Vargas, H., Quijano, F., Salcedo, M., and Marrero-Rodr’iguez, D. Revisiting the Genomic and Transcriptomic Landscapes From Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine. 05857. 2019 Arch Med Res (50):7.

Concepts Keywords
Adhesion Molecules Cervical non cancer
Breast Ovarian cervical cancers
Cancer RTT
Cervical Branches of biology
Chromosome Medicine
Diagnostic Test Biotechnology
Genetic Medical genetics
Gynaecological Cancer
Harbour Transcriptomics technologies
Incidence Molecular diagnostics
Malignancies Ovarian cancer
Metabolism DNA Chip
Microarray Transcriptomics
Molecular Markers
Mortality
Ovary
Pathogenic
Precision Medicine
Prognosis
Transcriptome
Transcriptomic

Semantics

Type Source Name
disease MESH Malignancies
drug DRUGBANK Aspartame
disease MESH cervical cancer
pathway KEGG Cell cycle
disease MESH diagnosis
disease MESH Breast cancer
pathway KEGG Breast cancer
disease MESH Ovarian cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *